Microbot Medical Inc.MBOTNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-44.69%
↓ 206% below average
Average (39q)
-14.58%
Historical baseline
Range
High:1586.76%
Low:-2453.53%
CAGR
+1.6%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -44.69% |
| Q2 2025 | 43.87% |
| Q1 2025 | -25.49% |
| Q4 2024 | -4.95% |
| Q3 2024 | 45.38% |
| Q2 2024 | 24.19% |
| Q1 2024 | 4.20% |
| Q4 2023 | -32.07% |
| Q3 2023 | 18.10% |
| Q2 2023 | -15.58% |
| Q1 2023 | -14.17% |
| Q4 2022 | -3.53% |
| Q3 2022 | -10.94% |
| Q2 2022 | 28.55% |
| Q1 2022 | -24.38% |
| Q4 2021 | 62.42% |
| Q3 2021 | 0.00% |
| Q2 2021 | 24.13% |
| Q1 2021 | 12.01% |
| Q4 2020 | -3.66% |
| Q3 2020 | 55.01% |
| Q2 2020 | -3.18% |
| Q1 2020 | -17.84% |
| Q4 2019 | -0.24% |
| Q3 2019 | 13.77% |
| Q2 2019 | 26.24% |
| Q1 2019 | -22.97% |
| Q4 2018 | 22.31% |
| Q3 2018 | -16.60% |
| Q2 2018 | 50.60% |
| Q1 2018 | 148.00% |
| Q4 2017 | -41.00% |
| Q3 2017 | -10.08% |
| Q2 2017 | 104.89% |
| Q1 2017 | 102.30% |
| Q4 2016 | -2453.53% |
| Q3 2016 | -90.80% |
| Q2 2016 | 1586.76% |
| Q1 2016 | -96.26% |
| Q4 2015 | -24.09% |